Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | ERAP1 | Q9NZ08 | 4/20 | 0.34 |
| ▸ | ANPEP | P15144 | 3/20 | 0.34 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.34 |
| ▸ | ACP3 | P15309 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | LAP3 | P28838 | 3/20 | 0.33 |
| ▸ | IL1RN | P18510 | 2/20 | 0.33 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP7 | P09237 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8625379 | 0.89 | PPARA (0.38) | ERAP1ANPEPERAP2ACP3LAP3 | |
| SCHEMBL8947039 | 0.88 | LAP3 (0.36) | ERAP1ANPEPERAP2ACP3LAP3 | |
| SCHEMBL8618813 | 0.88 | PPARA (0.37) | ANPEPLAP3FDFT1 | |
| SCHEMBL8824820 | 0.83 | LAP3 (0.33) | ANPEPACP3LAP3 | |
| SCHEMBL8947080 | 0.82 | AKR1C3 (0.35) | ANPEPACP3LAP3 | |
| SCHEMBL8623433 | 0.82 | SCN4A (0.39) | ANPEPACP3LAP3 | |
| SCHEMBL9167366 | 0.82 | ADRA2C (0.38) | ANPEPACP3LAP3 | |
| SCHEMBL8620463 | 0.79 | FDFT1 (0.38) | ANPEPACP3LAP3FDFT1 | |
| SCHEMBL8625231 | 0.79 | ACP3 (0.47) | ANPEPACP3LAP3 | |
| SCHEMBL8621528 | 0.79 | HTR2A (0.40) | HTR2AFDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | claimed |
| US-5567841-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |